Janux Therapeutics, Inc.

Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms. The company is focused on designing tumor-activated therapies that redirect immune cells against cancer while aiming to reduce the safety and pharmacokinetic limitations seen in earlier T-cell engager approaches.

−1 556,4 %

−1 136,3 %

−5,6 %

39.04

39.04

— Janux Therapeutics, Inc.
%
Clinical-stage oncology programs0% Lead drug candidates in human trials, including JANX007 and JANX008.
TRACTr platform45% Tumor-activated T cell engagers designed to direct CD3 T cells to tumors.
TRACIr platform25% Bispecific immunomodulators that combine tumor targeting with CD28 costimulation.
ARM platform15% Adaptive immune response modulators intended to broaden the immunotherapy pipeline.
Preclinical discovery pipeline15% Earlier-stage programs and target discovery work across oncology indications.

Janux does not sell approved products to end patients; its current business is built around advancing drug candidates...

  • Strategic collaboration partnersprimary

    Large pharma or biotech partners that may license, fund, or co-develop Janux programs to access its tumor-activated platforms.

  • Clinical trial ecosystemprimary

    Hospitals, investigators, and CRO-like service providers that support enrollment, testing, and execution of clinical studies.

  • Regulatory agenciesprimary

    FDA, European Commission, and other authorities that review safety and efficacy data before approval.

  • Future oncology treatment centersemerging

    Cancer hospitals and physician groups that would prescribe approved therapies if Janux reaches commercialization.

Janux is headquartered in San Diego, California, where it leases office and laboratory space and conducts its core...

  • •Headquartered in San Diego, California
  • •Leased office and laboratory space in San Diego
  • •Primary operations and R&D are in the United States
  • •Clinical and regulatory pathway includes FDA and European Commission
  • •Competitive landscape is global across U.S., Europe, and Asia

Janux’s strategy is to advance its tumor-activated immunotherapy platforms into the clinic and demonstrate a safety and...

01
Advance lead clinical programsshort-term

Clinical proof-of-concept is the main value driver for a pre-commercial biotech.

02
Differentiate tumor-activated immunotherapymedium-term

The company must show better safety than prior TCEs to win in a crowded field.

03
Secure external funding and partnershipsshort-term

Development costs are high and the company has no product revenue.

Janux is a speculative, pre-revenue biotech with a limited operating history, so clinical failure or delayed data can...

high

Clinical development failure

The company’s pipeline is early-stage and depends on positive safety/efficacy data.

Scope
JANX007, JANX008 and preclinical programs
Materiality
high
high

Financing risk

The company has no product sales and continues to burn cash on R&D.

Scope
Equity raises, collaboration funding, and operating runway
Materiality
high
medium

Competitive pressure

Large pharma and multiple biotech peers are pursuing similar immuno-oncology targets.

Scope
PSMA-targeting and T-cell engager markets
Materiality
high
medium

Regulatory and approval uncertainty

Future approvals depend on evolving FDA and EU expectations for class-wide data.

Scope
Clinical endpoints, safety profile, and labeling
Materiality
high
medium

Manufacturing and trial execution

Biologic drug development requires reliable CMC, site activation, and enrollment.

Scope
Clinical supply chain and outsourced research contracts
Materiality
medium
Collaboration revenue recognition
Can cause quarter-to-quarter revenue volatility
Research and development accruals
Affects operating expenses and liabilities
Stock-based compensation valuation
Influences G&A and R&D expense levels
Lease accounting
Creates right-of-use assets and lease liabilities

ALX ONCOLOGY HOLDINGS INC

ALXO · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

IONIS PHARMACEUTICALS INC

IONS · Pharmaceutical Preparations

Anixa Biosciences Inc

ANIX · Pharmaceutical Preparations

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

: 28.4.2026